First-line osimertinib in patients with epidermal growth factor receptor –mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

The AZENT (NCT02841579) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR)mutation –positive advanced non–small-cell lung cancer (NSCLC) and with a coexisting low allelic fraction of Thr790Met.

Source: European Journal of Cancer - November 8, 2021 Category: Cancer & Oncology Authors: Margarita Majem, Ivanna Sullivan, Santiago Viteri, Guillermo L ópez-Vivanco, Manuel Cobo, José M. Sánchez, Jorge García-González, Javier Garde, Miguel Sampayo, Griselda Martrat, Andrea Malfettone, Niki Karachaliou, Miguel A. Molina-Vila, Rafael Rosel Tags: Original Research Source Type: research